Showing results (101-110 of 190) with videos related to
Sort By:
Pageof 19
Cancer|July 15, 2010
Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology GroupJacob M Rowe, Haesook T Kim, Peter A Cassileth, et al.Journal of Cancer Research and Clinical Oncology|May 18, 2007
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer ConsortiumKim Margolin, Timothy W Synold, Primo Lara, et al.Blood|April 19, 2012
An activating intragenic deletion in NOTCH1 in human T-ALLJ Erika Haydu, Kim De Keersmaecker, Mary Kaye Duff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2004
Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology GroupMartin S Tallman, Haesook T Kim, Elisabeth Paietta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinomaRobert J Motzer, Gary R Hudes, Brendan D Curti, et al.Medical Oncology (Northwood, London, England)|July 2, 2003
Metastatic choriocarcinoma in a middle-aged man presenting as a right thigh mass with venous thrombosis: a case reportIlya Blokh, Stanley J Oiseth, Joachim Fuks, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.The Oncologist|September 10, 2008
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinibMario E Lacouture, Shenhong Wu, Caroline Robert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2004
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinomaMichael B Atkins, Manuel Hidalgo, Walter M Stadler, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group studyJoseph I Clark, Jessica Mehrabi, Jeffrey A Sosman, et al.Pageof 19